Dorian. I'm not sure he will need a lawyer. I think this guy is Peggy from the Discover Card commercial that resides in Russia on the Call Center customer center phone lines. It's obvious he can't spell or write clearly.
How about providing a link, or copy and paste, or some article that proves your statement. They are called facts. Please inform us. It's not that we don't want to take your word, but facts are much better.
Will Lewis said by midyear. I take that as June-July or 4-5 months. On page 17 in February 2014 Investor Presentation under Key Takaways and Two Near Term Commercial Opportunities, it states: Europe:
Arikace EMA filing for CF in 1st Half 2014.
On page 24 of November 2013 Investor Presentation, under 1st Half 2014, it states, "Estimated Filing for CF Indication in Europe/Canada.
I don't read that as a delay, but I don't have an agenda like you. It doesn't mention Japan in either of those. If they get it great, but it may not be the priority now. Your immaturity is overwhelming this board. Your like the little kid in the schoolyard stating "I know you are, but what am I?"
Your problem is you don't know the difference between fact and fiction, and you couldn't provide Facts even if you wanted. The #$%$ is the stuff on your face thats replaces the egg.
Hey Terry, read it again. Last word from Lewis says "midyear" You are one lying FOS Loser!!!
Further, we believe that
once-daily administration of ARIKACE will support patient convenience and compliance,” said Will Lewis, President and Chief Executive
Officer of Insmed. “With the results achieved in our Phase 3 trial, along with these positive interim data, we continue our preparation for
regulatory filings with the European Medicines Agency and Health Canada, which remain on target for mid-year.”
140 Ids. The challenge was to prove the" Pohaler results" were better in their Phase III results, and that "durability is overblown" Surely you have some statistical data to prove the "overblown" statement. Or are you just taking your head out of your orifice for a breather, and saying the first thing that comes to mind.
140 IDs. I guess your estimate is based upon your DD. Care to share where you obtain that information? Or can't you?
Bo. What's confusing is when I spoke to IR last week on Wednesday?, they had mentioned that Wedbush was the only analyst to downgrade. Did UBS come out with something on Wed - Fri?
If you read Seeking Alpha, they are mentioning the Wedbush downgrade to $7, but also UBS. I thought I read somewhere on this MB that UBS did not downgrade. Can anyone verify? Thanks
Look in the mirror you idiot. Instead of saying check Novartis website, why don't you copy and paste for us the items you want to share with us. We don't have crystal balls, and we certainly don't know what items you want to mislead us on. So, show us some FACTS. BY the way, you don't scan this message board, you live it!!
You write as well as Terry, and have the same amount of self congratulatory humility you'd expect from an alter ego.